1. Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42(3):474–83.
2. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–62.
3. Imfinzi™ (durvalumab): US prescribing information. 2017. https://www.fda.gov . Accessed 24 May 2017.
4. AstraZeneca. Durvalumab granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer [media release]. 17 Feb 2016. http://www.astrazeneca.com .
5. AstraZeneca. US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer [media release]. 9 Dec 2016. http://www.astrazeneca.com .